SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--To improve the assessment of how cancer patients are responding to investigational therapies in clinical trials, MEDIAN Technologies (Paris:ALMDT)(ALMDT) today announced a strategic agreement with Quintiles to offer advanced integrated image services to biopharmaceutical customers worldwide.
